Vergent Bioscience Inc. raised $21.5 million in a series B financing round to advance development of VGT-309, its targeted fluorescent imaging agent that illuminates tumors during open, minimally invasive and robotic-assisted surgeries. The company plans to use the funds to support a phase II trial at the University of Pennsylvania that focuses on lung cancer and a multicenter study that will examine the agent’s use in other indications.
Cleara Biotech BV has closed a $2.5 million seed financing round, the proceeds of which will be used to progress its compounds toward clinical development and build the company's developmental pipeline.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has identified Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.
Researchers have identified an RNA-binding protein that played a role in colon cancer relapse, offering new insights into how cells persist in the presence of chemotherapy.
